Market cap
₹20,206 Cr
NSE: ONESOURCE | BSE: 544292
₹1,834.80
As on 29-Apr-2026 10:29IST
Market cap
₹20,206 Cr
Revenue (TTM)
₹1,419 Cr
P/E Ratio
1005.2
P/B Ratio
3.5
Div. Yield
0 %
Quality Score
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹20 Cr
ROE
-0.6 %
ROCE
2.6 %
Industry P/E
46.42
EV/EBITDA
51.4
Debt to Equity
0.1
Book Value
₹507.4
EPS
₹2.4
Face value
1
Shares outstanding
114,642,651
CFO
₹--
EBITDA
₹--
Net Profit
₹--
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Onesource Specialty Pharma
| 1.3 | 26.8 | 58.8 | 15.3 | -- | -- | -- |
|
BSE Healthcare
| 3.2 | 5.7 | 8.6 | 5.3 | 24.8 | 14.0 | 11.2 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Onesource Specialty Pharma
|
1,834.8 | 20,205.8 | 1,419.3 | 20.1 | 8.4 | 0.5 | 1005.2 | 3.5 |
| 2,485.0 | 20,207.0 | 1,215.1 | 284.8 | 28.7 | 21.1 | 70.4 | 13.3 | |
| 756.0 | 14,935.9 | 7,266.8 | 627.5 | 11.9 | 12.6 | 23.7 | 2.7 | |
| 714.7 | 17,470.9 | 5,092.5 | 545.5 | 15.9 | 14.1 | 32 | 3.9 | |
| 932.3 | 14,987.6 | 7,918.4 | 429.9 | 10.7 | 7.2 | 34.6 | 2.3 | |
| 1,105.0 | 19,596.4 | 4,560.2 | 1,544.6 | 35.1 | 19.2 | 12.6 | 2.2 | |
| 167.3 | 21,839.6 | 8,871.4 | -223.5 | 1.9 | -1.6 | -- | 2.7 | |
| 969.0 | 15,744.8 | 1,284.3 | 134.4 | -- | 30.7 | 117.2 | 12.9 | |
| 436.2 | 17,729.3 | 3,720.2 | 352.1 | 13.7 | 8.2 | 50.4 | 3.7 | |
| 1,414.1 | 23,027.6 | 3,151.0 | -10.0 | 8.4 | 2.5 | 1046.7 | 5.0 |
No Review & Analysis are available.
OneSource Specialty Pharma Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biological drug products in various injectable formats in India, Ireland, the United States, and... internationally. The company provides end-to-end contract development and manufacturing operations (CDMO) services across various phases of preclinical and clinical development and commercial supply of biologics. It also offers drug-devices, including prefilled syringes, dial and push variable and fixed dose pen injectors, pull push fixed dose pens, and autoinjectors; sterile injectables; soft gelatin capsules; and biologics solutions for microbial and mammalian cell line biopharmaceuticals, cell and gene therapy, and RNA products. The company was formerly known as Stelis Biopharma Limited and changed its name to OneSource Specialty Pharma Limited in February 2024. OneSource Specialty Pharma Limited was incorporated in 2007 and is based in Bengaluru, India. Read more
Incorporated
2007
Chairman
Arun Kumar
Managing Director
Neeraj Sharma
Headquarters
Navi Mumbai, Maharashtra
Website
Annual Reports
Announcements
View AnnouncementsNo News & Announcements are available.
The share price of Onesource Specialty Pharma Ltd is ₹1,834.80 (NSE) and ₹1,832.90 (BSE) as of 29-Apr-2026 10:29 IST. Onesource Specialty Pharma Ltd has given a return of 15.29% in the last 1 years.
Since, TTM earnings of Onesource Specialty Pharma Ltd is negative, P/E ratio is not available.
The P/B ratio of Onesource Specialty Pharma Ltd is 3.47 times as on 28-Apr-2026, a 7 discount to its peers’ median range of 3.73 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
0.00
|
3.41
|
|
2024
|
0.00
|
0.00
|
|
2023
|
0.00
|
0.00
|
|
2022
|
0.00
|
0.00
|
|
2025
|
0.00
|
3.41
|
The 52-week high and low of Onesource Specialty Pharma Ltd are Rs 2,248.00 and Rs 1,057.00 as of 29-Apr-2026.
Onesource Specialty Pharma Ltd has a market capitalisation of ₹ 20,206 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Onesource Specialty Pharma Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.